New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
HRTS ETF · Tema GLP-1, Obesity & Cardiometabolic ETF
The HRTS Exchange Traded Fund (ETF) is provided by Tema. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Today at 1:47 PM UTC
LIVE
CLOSED
This fund is part ofTomorrow's Treatments1M perf.-0.95%
Last price
$34.28
+0.67%
1M perf.
-5.47%
1M flows
N/A
AuM
€45M
E/R
0.99%
Rating
Not rated
ESG Consensus®
HRTS
$34.28
+0.67%
Performance & flows
Segment for quartile rank
December 16, 2025 → March 16, 2026
Create a free account to view the flows graph
HRTS
$34.08
-2.47%
Tomorrow's Treatments
+2.00%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -5.47%  | -2.47%  | +14.37% | N/A | N/A | -5.73% | -3.53% | -3.53% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/16/2026
$34.08
1D NAV change
+1.20%
Dividend policy
No. of holdings
44
Inception date
11/21/2023
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
Tema GLP-1, Obesity & Cardiometabolic ETF (the “Fund”) seeks to provide long-term growth of capital.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
JDOC
1M perf.
-5.24%
E/R
0.65%
XDG3
1M perf.
-6.02%
E/R
0.35%
BGHC
1M perf.
-5.55%
E/R
0.97%
WEL9
1M perf.
-2.98%
E/R
0.18%
VHT
1M perf.
-3.99%
E/R
0.09%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -2.47% | +14.37% | N/A | N/A |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
82.17%
Denmark
4.79%
United Kingdom
4.35%
Switzerland
3.21%
Ireland
2.97%
Japan
1.72%
Unavailable
0.79%
Sectors
Health Care
87.29%
Unavailable
12.71%
Diversification
Total weight of top 15 holdings out of 44
Top 15 holdings
Data as of January 31, 2026
LILLY
US7711951043
JOHNSON&JOHNSON
ASTRAZENECA
THERMO FISHER SCIENTIFIC
MERCK & CO INC
UNITEDHEALTH GRP
DK0062498333
Create a free account to view top holdings
GILEAD SCIENCES
NOVARTIS
ABBOTT LABS
BOSTON SCIENTIFIC
MEDTRONIC PLC
VERTEX PHARMACEUTICALS
DANAHER
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Tema
Tema ID Card
Number of funds
9
Total AuM
€1.5B
Expense ratio range
0.18% - 0.99%
Average expense ratio
0.7544%
Top 5 funds by Tema
| AuM | ||
|---|---|---|
DSPY | Tema S&P 500 Historical Weight ETF Strategy | €679M |
VOLT | Tema Electrification ETF | €380M |
RSHO | Tema American Reshoring ETF | €209M |
CANC | Tema Oncology ETF | €145M |
HRTS | Tema GLP-1, Obesity & Cardiometabolic ETF | €45M |
Frequently asked questions about HRTS
What does Tema GLP-1, Obesity & Cardiometabolic ETF, HRTS, invest in?
HRTS is a Active ETF. This ETF provides exposure to Other Equities.
What is the Total Expense ratio (TER) of HRTS?
HRTS carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.
When was HRTS launched?
HRTS was introduced to the market on November 21, 2023. It trades on United States
Who is the ETF issuer of HRTS?
Tema GLP-1, Obesity & Cardiometabolic ETF, HRTS, is provided by Tema. Learn more about Tema here.
What is the current assets under management (AUM) of HRTS?
HRTS oversees €45M in assets as of March 16, 2026.
How has HRTS performed lately?
Based on data from March 16, 2026, HRTS returned -5.47% over the past month, -2.47% over the last three months and -3.53% year-to-date.
What are the latest inflows or outflows for HRTS?
As of March 16, 2026, HRTS recorded net flows of -€586K year-to-date.
Does HRTS distribute dividends?
HRTS follows a distributing dividend policy, meaning it pays out income to investors. As of March 16, 2026, its 12-month trailing yield was 1.39%.
What are the main country or region exposures of HRTS?
As of January 31, 2026, HRTS has significant geographic allocations in USA, Denmark and United Kingdom.
In which sector or theme does HRTS invest in?
As of January 31, 2026, HRTS focuses largely on Health Care.
How many securities does HRTS hold and how diversified is it?
As of January 31, 2026, HRTS holds 44 positions in its portfolio, with 61.09% of assets concentrated in its top 15 holdings.
What are the main positions in HRTS?
As of January 31, 2026, HRTS top three holdings include LILLY, US7711951043 and JOHNSON&JOHNSON.
What is the base currency of HRTS?
The base currency of HRTS is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
